Replies to post #9685 on Ariad Pharmaceuticals Inc fka ARIA

[rkrw]

Getting into BRAF would be surprising to me.

On the analyst day call Clackson did say Ariad has had a long running interest in the EGFR T790 mutation, so maybe they have or had an independent program to '113 for EGFR and T790.